Andrew Ahmann
Overview
Explore the profile of Andrew Ahmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Beck R, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al.
JAMA
. 2017 Jan;
317(4):371-378.
PMID: 28118453
Importance: Previous clinical trials showing the benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly have included adults using insulin pumps, even though the majority...
12.
Ahmann A
Drugs Context
. 2015 Dec;
4:212288.
PMID: 26633984
Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose...
13.
Bailey T, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, et al.
Diabetes Technol Ther
. 2014 Apr;
16(5):277-83.
PMID: 24758729
Objective: This study evaluated the performance and acceptability of the Enlite(®) glucose sensor (Medtronic MiniMed, Inc., Northridge, CA). Subjects And Methods: Ninety adults with type 1 or type 2 diabetes...
14.
Ahmann A, Szeinbach S, Gill J, Traylor L, Garg S
Diabetes Technol Ther
. 2013 Nov;
16(2):76-83.
PMID: 24266497
Objectives: This study aimed to examine healthcare provider (HCP) recommendations and patient preferences for the insulin pen versus vial-and-syringe in patients with type 2 diabetes mellitus (T2DM) and to assess...
15.
Klonoff D, Bergenstal R, Garg S, Bode B, Meredith M, Slover R, et al.
J Diabetes Sci Technol
. 2013 Aug;
7(4):1005-10.
PMID: 23911183
Nocturnal hypoglycemia is a barrier to therapy intensification efforts in diabetes. The Paradigm® Veo™ system may mitigate nocturnal hypoglycemia by automatically suspending insulin when a prespecified sensor glucose threshold is...
16.
Long S, Rieck M, Sanda S, Bollyky J, Samuels P, Goland R, et al.
Diabetes
. 2012 Jun;
61(9):2340-8.
PMID: 22721971
Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in...
17.
Bergenstal R, Tamborlane W, Ahmann A, Buse J, Dailey G, Davis S, et al.
Diabetes Care
. 2011 Sep;
34(11):2403-5.
PMID: 21933908
OBJECTIVE To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained...
18.
Ahmann A
Am J Manag Care
. 2011 Apr;
17(2 Suppl):S41-51.
PMID: 21517656
Comparative effectiveness research (CER) is a relatively new strategy in drug development and healthcare designed to aid consumers, clinicians, purchasers, and policy makers in determining the best treatment options for...
19.
Caddell K, Komanapalli C, Slater M, Hagg D, Tibayan F, Smith S, et al.
Ann Thorac Surg
. 2010 Nov;
90(6):1818-23.
PMID: 21095317
Background: Maintenance of appropriate capillary blood glucose in cardiovascular surgery patients has been associated with improved outcomes, including lower mortality. Interpatient variability in insulin resistance can make management difficult, leading...
20.
Bergenstal R, Tamborlane W, Ahmann A, Buse J, Dailey G, Davis S, et al.
N Engl J Med
. 2010 Jul;
363(4):311-20.
PMID: 20587585
Background: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors. Methods: In this 1-year, multicenter, randomized, controlled trial,...